|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials显示文摘Hepatocellular carcinoma(HCC), the predominant form of primary liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancerrelated death. The difficulty to diagnose early cancer stages, the aggressive behaviors of HCC, and the poor effectiveness of therapeutic treatments, represent the reasons for the quite similar deaths per year and incidence number. Considering the fact that the diagnosis of HCC typically occurs in the advanced stages of the disease when the therapeutic options have only modest efficacy, the possibility to identify early diagnostic markers could be of significant benefit. So far, a large number of biomarkers have been associated to HCC progression and aggressiveness, but many of them turned out not to be of practical utility. This is the reason why active investigations are ongoing in this field. Given the huge amount of published works aimed at the identification of HCC biomarkers, in this review we mainly focused on the data published in the last year, with particular attention to the role of(1) molecular and biochemical cellular markers;(2) micro-interfering RNAs;(3) epigenetic variations; and(4) tumor stroma. It is worth mentioning that a significant number of the HCC markers described in the present review may be utilized also as targets for novel therapeutic approaches, indicating the tight relation between diagnosis and therapy. In conclusion, we believe that integrated researches among the different lines of investigation indicated above should represent the winning strategies to identify effective HCC markers and therapeutic targets. | Bruna Scaggiante Maryam Kazemi Gabriele Pozzato Barbara Dapas Rosella Farra Mario Grassi Fabrizio Zanconati Gabriele Grassi | 2014 | World Journal of Gastroenterology2014，20，5： | 13 |
| 2 | Cell-free DNA integrity for the monitoring of breast cancer:Future perspectives?显示文摘Breast cancer(BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted genes in plasma/serum is a limiting factor. A possible approach overtaking this problem comes from the measurement of cell-free DNA integrity, which is an independent factor from the mutational status and theoretically is representative of all tumors. This review summarizes the state-of-the-art of cell-free DNA integrity researches in BC, the controversies and the future perspective. | Navid Sobhani Daniele Generali Fabrizio Zanconati Marina Bortul Bruna Scaggiante | 2018 | World Journal of Clinical Oncology2018，9，2： | 2 |
| 3 | Effects of E2F1–cyclin E1–E2 circuit down regulation in hepatocellular carcinoma cells显示文摘 | Rossella Farra Barbara Dapas Gabriele Pozzato Bruna Scaggiante Francesco Agostini Cristina Zennaro Mario Grassi Natalia Rosso Carlo Giansante Nicola Fiotti Gabriele Grassi | 2011 | Digestive and Liver Disease2011，，12： | 1 |
| 4 | Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels显示文摘 | Daniele Baiz Gabriele Pozzato Barbara Dapas Rossella Farra Bruna Scaggiante Mario Grassi Laura Uxa Carlo Giansante Cristina Zennaro Gianfranco Guarnieri Gabriele Grassi | 2008 | Biochimie2008，，3： | 1 |
| 5 | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer显示文摘Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and it is usually treated with anti-oestrogen drugs. However, the majority of hormone receptor positive metastatic BC patients develop resistance to anti-oestrogen treatments.The need for more down-stream therapies brought to the development of therapeutic strategies inhibiting the phosphatidylinositol 3-kinase-mammalian target of rapamycin (mTOR) pathway. Inhibitors of the mTOR have been tested in different clinical trials; everolimus has been Food and Drug Administration approved for the treatment of oestrogen receptor positive/human epidermal growth factor receptor 2 negative BC patients in combination with exemestane in patients who have progressed to anastrozole or letrozole after the encouraging results coming from BOLERO-2 trial. Similar results were obtained by the TAMRAD investigatory study testing tamoxifen in combination with everolimus in advanced BC. This editorial focuses on the results from BOLERO-2, BOLERO 4 and BOLERO-6, which tested the clinical importance of mTOR inhibition. We comment also on the role of phosphatidylinositol 3-kinase-mTOR inhibition as reported in the BELLE-2 and BELLE-3 trials and the future directions for the inhibition of this tumour metabolic axis. | Navid Sobhani Daniele Generali Fabrizio Zanconati Marina Bortul Bruna Scaggiante | 2018 | World Journal of Clinical Oncology2018，9，8： | 0 |
| 6 | Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer显示文摘Metastatic castrate-resistant prostate cancer remains a disease hard to cure,and for this reason predictive tools to monitor disease progression and therapy response are an urgent need.In this respect,liquid biopsy on circulating cell-free nucleic acids represents an interesting strategy based on robust data.The low invasiveness and the possibility to target circulating cell-free tumor deoxyribonucleic acid underline the high specificity,sensitivity and clinical usability of the technique.Moreover,it has been observed that the cell-free tumor deoxyribonucleic acid of metastatic castrate-resistant prostate cancer patients can be representative of the tumor heterogeneity.Cell-free tumor deoxyribonucleic acids express the same behaviors as mutations:Variation in gene copy number or the methylation rate of the tumor tissue.Recently,circulating cell-free ribonucleic acid molecules have emerged as interesting markers to stratify the disease.Due to high-throughput technologies,liquid biopsy on circulating cell-free nucleic acids will soon be utilized in the clinical management of metastatic castrate-resistant prostate cancer patients. | Navid Sobhani Marianna Sirico Daniele Generali Fabrizio Zanconati Bruna Scaggiante | 2020 | World Journal of Clinical Oncology2020，11，7： | 0 |
| 7 | Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines显示文摘AIM:To evaluate the effects of the proteasome inhibitor bortezomib(BZB)on E2Fs and related genes in hepatocellular carcinoma(HCC)cells.METHODS:The mRNA levels of the E2F family members(pro-proliferative:E2F1-3 and anti-proliferative:E2F4-8)and of their related genes cyclins and cyclindependent kinases(cdks)were evaluated in two HCC cell lines following a single BZB administration.mRNA levels of the epithelial-mesenchymal transition(EMT)genes were also measured in both cell lines after BZB treatment.The BZB concentration(40 nmol/L)used was chosen to stay well below the maximal amount/cm2recommended for in vivo application,and 2 d incubation was chosen as this time point has been found optimal to detect BZB effects in our previous studies.The HCC cell lines,HepG2 and JHH6,were chosen as they display different phenotypes,hepatocyte-like for HepG2and undifferentiated for JHH6,thus representing an in vitro model of low and high aggressive forms of HCC,respectively.The mRNA levels of the target genes were measured by two-color microarray-based gene expression analysis,performed according to Agilent Technologies protocol and using an Agilent Scan B.For the E2F family members,mRNA levels were quantified by realtime reverse transcription polymerase chain reaction(RT-PCR).Using small interfering RNA’s,the effects of E2F8 depletion on cell number was also evaluated.RESULTS:After BZB treatment,microarray analysis of the undifferentiated JHH6 revealed a significant decrease in the expression of the pro-proliferative E2F member E2F2.Quantitative RT-PCR data were in keeping with the microarray analysis,and showed a significant increase and decrease in E2F8 and E2F2 mRNA levels,respectively.In contrast,BZB treatment of the hepatocyte-like HCC cell line HepG2 had a significant impact on mRNA levels of 5 of the 8 E2F members.In particular,mRNA levels of the pro-proliferative E2F members E2F1,E2F2,and of the anti-proliferative member E2F8,decreased over 80%.Notably,a reduction in E2F8 expression in HepG2 and JHH6 cells following siRNA treatment had no impact on cell proliferation.As observed with JHH6,BZB treatment of HepG2cells induced a significant increase in mRNA levels of an anti-proliferative E2F member,E2F6 in this case.As was observed with E2F’s,more dramatic changes in mRNA levels of the E2F related genes cyclins and Cdks and EMT genes were observed after BZB treatment of HepG2 compared to JHH6.CONCLUSION:The differential expression of E2Fs and related genes induced by BZB in diverse HCC cell phenotypes contribute to bortezomib’s mechanism of action in hepatocellular carcinoma. | Daniele Baiz Barbara Dapas Rossella Farra Bruna Scaggiante Gabriele Pozzato Fabrizio Zanconati Nicola Fiotti Lara Consoloni Sara Chiaretti Gabriele Grassi | 2014 | World Journal of Gastroenterology2014，20，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员